Effect of Metformin on Glycemic Control Regarding Carriers of the SLC22A1/OCT1 (rs628031) Polymorphism and Its Interactions with Dietary Micronutrients in Type 2 Diabetes

• Published in: Diabetes, metabolic syndrome and obesity Vol. 15; pp. 1771 - 1784
• Main Authors: Zepeda-Carrillo, Eloy A, Ramos-Lopez, Omar, Martínez-López, Erika, Barrón-Cabrera, Elisa, Bernal-Pérez, J Antonio, Velasco-González, Luisa E, Rangel-Rios, Ernesto, Bustamante Martínez, J Fausto, Torres-Valadez, Rafael
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 30.06.2022; Dove; Dove Medical Press
• Subjects: Analysis; calcium intake; Diabetes therapy; Diet therapy; gene-nutrient interactions; Genetic aspects; Genetic polymorphisms; Glibenclamide; Glycosylated hemoglobin; Metformin; nutrigenetic; Original Research; pharmacogenetic; potassium intake; slc22a1/oct1 gene; Type 2 diabetes; Mexico
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S354579

Purpose: Differences in metformin effect on glycemic control in type 2 Diabetes (T2D) have been associated with diet, obesity, years since T2D diagnosis and genetic factors, such as the Met408Val (rs628031) SLC22A1/OCT1 gene polymorphism. This study aimed to analyze the effect of metformin and diet on glycemic control and its association with the Met408Val polymorphism in patients with T2D from western Mexico. Patients and Methods: A total of 240 T2D adult patients were enrolled in this cross-sectional study. Anti-hyperglycemic therapy, dietary intake, body composition and glycemic profile were recorded and the determination of genotypes of SLC22A1/OCT1 gene (rs628031) was performed using an allelic discrimination assay. Results: The type of metformin therapy was 47% monotherapy, 45% dual therapy (metformin+glibenclamide or metformin+insulin) and 8% triple therapy (metformin+glibenclamide+insulin). Individuals with metformin monotherapy had a higher glycemic control frequency (%HbA1c <7.0) compared with the dual and triple treatment schemes (77% vs 35% and 15%, respectively; p<0.001). Interestingly, a high potassium intake was documented in the three anti-hyperglycemic therapies and a lower intake of micronutrients, including calcium, magnesium, and zinc. An interaction was found between calcium intake and carriers of the risk allele A (408Val) with %HbA1c (P interaction=0.028), and potassium intake with the TyG index (P interaction=0.027). In addition, there was a positive correlation between calcium intake and %HbA1c (r=0.682; p=0.010), and potassium intake vs TyG index (r=0.593; p=0.033) in risk allele A (408Val) carriers with metformin monotherapy. Genotype frequencies were GG homozygotes (76.6%), GA heterozygotes (21.5%) and AA homozygotes (1.9%). The allele frequency was 87.4% for the ancestral allele G and 12.6% for the risk allele A. Conclusion: These findings suggest a differing effect of metformin on glycemic control regarding calcium and potassium intake and the Met408Val SLC22A1/OCT1 gene polymorphism in T2D patients. Keywords: nutrigenetic, pharmacogenetic, SLC22A1/OCT1 gene, gene-nutrient interactions, calcium intake, potassium intake